---
title: Knee Osteoarthritis and IPACK
nct_id: NCT06712394
overall_status: NOT_YET_RECRUITING
sponsor: Sakarya University
study_type: OBSERVATIONAL
primary_condition: Osteoarthritis, Knee
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06712394.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06712394"
ct_last_update_post_date: 2024-12-02
last_seen_at: "2026-05-12T06:22:12.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Knee Osteoarthritis and IPACK

**Official Title:** Interspace Between the Popliteal Artery and Capsule of the Posterior Knee-

**NCT ID:** [NCT06712394](https://clinicaltrials.gov/study/NCT06712394)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 120
- **Lead Sponsor:** Sakarya University
- **Conditions:** Osteoarthritis, Knee
- **Start Date:** 2025-01-01
- **Completion Date:** 2025-07-01
- **CT.gov Last Update:** 2024-12-02

## Brief Summary

Interspace between the Popliteal Artery and Capsule of the posterior Knee (IPACK) block involves ultrasound-guided local anesthetic infiltration of the space between the popliteal artery and the posterior knee joint capsule.

The purpose of the study; To investigate the effectiveness of this block applied to knee osteoarthritis in clinical practice.

In this study, patients who underwent IPACK block by the practitioner; Demographic data, medications used, block success, block characteristics and block-related complications will be recorded observationally. Before and after the block procedure, patients' pain was measured with the Numeric Rating Scale (NRS) at 1st and 3rd months, their disability levels were measured with The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire and Short Form-12 (Short Form). Quality of life will be measured with the -SF-12) survey.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 90 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients suffering from grade 3 and 4 knee osteoarthritis

Exclusion Criteria:

* Patients who have had previous knee surgery
* Patients who have had any knee injection in the last 3 months
* Malignancy
* Inflammatory disease
* Infectious disease (local or general)
```

## Arms

- **IPACK** — IPACK block involves ultrasound-guided local anesthetic infiltration of the space between the popliteal artery and the posterior knee joint capsule.

## Interventions

- **IPACK** (PROCEDURE) — The IPACK block involves infiltration of the space between the popliteal artery and the posterior knee joint capsule with 20 ml of 0.25% local anesthetic (bupivacain) under ultrasound guidance.

## Primary Outcomes

- **Pain assessment** _(time frame: 1st and 3rd month after the procedure)_ — The Numeric Rating Scale (NRS) is a frequently used tool for assessing and monitoring the severity of pain. The pain scale measures on an 11-point rating system, where 0 indicates the absence of pain and 10 represents the most severe pain one can imagine. Patients are requested to assess their pain on a scale ranging from 0 to 10. The physician obtained from measurements at each visit by directly questioning the patient.
- **Functional status** _(time frame: 1st and 3rd month after the procedure)_ — The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is widely used in the evaluation of knee osteoarthritis. It is a self-administered questionnaire consisting of 24 items divided into 3 subscales: pain, stiffness, and physical function. The questionnaire evaluates activities of daily living and functional mobility. The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). The scores for each subscale are summed up, with a possible score range of 0-20 for pain, 0-8 for stiffness, and 0-68 for physical function. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.

## Secondary Outcomes

- **Quality of life assessment** _(time frame: 1st and 3rd month after the procedure)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06712394.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06712394*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*